N/A N=40 A Pilot of the Brief Relationship Checkup
Relationship Distress
Primary: Relationship Functioning — 84.99; 90.90 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=750 Increasing Engagement and Improving HIV Outcomes Via HealthMPowerment
HIV Infections · Sexually Transmitted Diseases · Stigma, Social
Primary: Percent of Participants Reporting Changes in Their HIV Testing Behavior Using Self-report Questionnaires — 185; 171; 2 Participants
Phase 1 N=56 Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors
Advanced Solid Tumors · Metastatic Melanoma
Primary: Maximum Concentration (Cmax) of Plasma Midazolam on Day -7, Day 1, and Day 14 — 9.45; 11.1; 2.44 nanograms per milliliter (ng/mL)
N/A N=5,506 Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)
Prostatic Neoplasms, Castration-Resistant
Primary: Overall Survival (OS): Inverse Probability Treatment Weighting (IPTW) — 20.6; 22.5 Months
N/A N=1,454 FIRMAGON® Intensive Drug Monitoring
Prostate Cancer
Primary: Percentage of Participants With Any Adverse Events (AEs) — 95 Participants
Phase 3 N=46 Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy
Obesity
Primary: Weight — 127; 130; 126; 75 kilograms
N/A N=73 Descriptive Observational Study ALK-2016-CPHG
NSCLC · Crizotinib · ALK Gene Rearrangement or ROS1 Gene Rearrangement
Primary: Age: Line of Treatment — 62.3; 63.1; 56.5; 64.3 Years
N/A N=7 Validation of User Needs of the Point Digit With Partial Hand Amputees
Amputation; Traumatic, Hand
Primary: VAL-1: System Comfort Validation Test — 100 % of participants who Passed test
N/A N=154 A Study to Evaluate Changes in Smokers Using An Oral Tobacco-Derived Nicotine Product
Tobacco Use
Primary: Summary Statistics of Percent Change From Baseline for Urinary Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) (%) (Per-Protocol Population) — 3.8; 13.8…
Phase 4 N=101 Prospective Evaluation of Facial Cosmetic Procedures
Cosmetic Techniques
Primary: Patient Satisfaction With Validated FACE-Q Aesthetics Survey — 28.0; 24.0; 36.0; 36.0 score on a scale
N/A N=31 Nicotine Pharmacokinetics and Subjective Effects of Nicotine Pouch 1.0 Compared to Velo® Ice Cool and Zyn® Cool Mint Mini Dry in Healthy Smokers
Smoking · Nicotine
Primary: Background-corrected Maximum Plasma Concentration [Cmax] — 8.109; 11.48; 2.629; 3.464 ng/mL
N/A N=24 A Research Program Targeting Pre- and Peri-transplant Optimization Program (R-PPOP)
Hematologic Malignancy
Primary: Number of Participants Who Completed at Least Half of Their High Intensity Interval Training Sessions — 9 Participants
Phase 2 N=197 ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
COVID-19 Disease
Primary: Severe Acute Respiratory Syndrome (SARS) Coronavirus (CoV)-2 Index Virus Neutralizing Antibody Titers at 2 Weeks After the Last Vaccination — 516.7; 970.9; 978.9 titer
Phase 2 N=102 A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
Dyslipidemia · Hypercholesterolemia · High Cholesterol
Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] — -0.78; -25.90; -33.78; -36.80 percent change from baseline — p=<.0001
Phase 3 N=275 Open-label Study of ASP2151 in Herpes Simplex Patients
Herpes Simplex
Primary: Percentage of Participants With Healing by Day 8 — 194 Participants